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peridol and fluphenazine.3 Bromocriptine, a selective D2 dopaminergic agonist, also stimulates ADH secretion in normal subjects,4 and has been reported to cause hyponatraemia, probably by this mechanism. 5 Hence it is possible that chronic blockade of dopamine receptors on magnocellular neurons by flupenthixol, a combined DI D2 dopaminergic antagonist, may have rendered them supersensitive to the effects of dopamine formed from the prescribed L-dopa. Recent One month after nephrectomy, the urine showed proteinuria (1 +) and numerous dysmorphic erythrocytes. He was put on oral cyclophosphamide (100 mg/ day) and prednisolone (60 mg/day). Over the next 3 months, the urinary abnormalities cleared and renal function returned to normal. Repeat computed tomographic scans showed no tumour relapse or metastases. Twenty months after nephrectomy, purpuric lesions and arthritis similar to those of the initial presentation appeared with active urinary sediment and deranged renal function (BUN 7 mmol/l; creatinine 146 mmol/l). The recurrence as with the original episode was antineutrophil cytoplasmic antibody negative. In view of the recurrence of CLV and microscopic polyarteritis of the solitary left kidney, therapy with cyclophosphamide and prednisolone was reinstituted, and one month later neither vasculitis nor tumour metastases was seen. The patient was seen 24 months later without relapse of CLV or neoplasia.
Paraneoplastic manifestations of renal cancer (internist's tumour) are frequent and numerous.4 Renal tumour antigen may bind up in circulating immune complexes and induce CLV' by activating the complement cascade causing lysosomal enzyme release from the accumulated polymorphonuclear cells leading to vessel wall injury, thrombosis, and haemorrhage.5 CLV has not hitherto been recognized as a cutaneous paraneoplastic syndrome. It should perhaps be included in the long list of paraneoplastic manifestations of renal cancer, although the relapse of CLV without apparent recurrence of tumour suggest coincidence. showed segmental defects in the right middle and left lower lobes. A radionuclide venography of the legs was normal. Treatment with heparin was continued, symptoms gradually subsided, and the patient was discharged 8 days later with oral warfarin. During the hospital course, tests for rheumatoid factor, anti-nuclear antibodies, VDRL, cryoglobulins, antibodies to extractable nuclear antigen (ENA), serum electrophoresis, and the cervical spine and mains X-ray films were negative or normal. After stopping warfarin 6 months later, a coagulation study including prothrombin time, partial thromboplastin time, thrombin time, Howell time, fibrinogen, antithrombin III, protein C, plasminogen, tissue thromboplastin inhibition (TTI) test and platelet neutralization procedure (PNP) test, was normal; serum anti-cardiolipin antibodies were negative and a nailfold capillaroscopy was normal.
Raised blood viscosity, enhanced platelet aggregation and abnormalities in coagulation-fibrinolytic activity, have been reported in patients with Raynaud's phenomenon, especially in the secondary form.'-5 In view of those abnormalities all leading to a hypercoagulable state, it is tempting to speculate that our patient's subclavian vein thrombosis was associated with her underlying disease, although her basic coagulation study was normal. We await further reports of similar cases, which would strengthen this impression.
Acute granulocytopenia in concomitant treatment of clozapine and methimazole Sir, The major agents employed in the chemotherapy of thyrotoxicosis are drugs of the thionamide class. Methimazole is one of the most widely used anti-thyroid agents. Adverse reactions occur in a small percentage of patients taking methimazole. The most significant ofthese are skin rash, drug fever, and agranulocytosis (0.1%). Of these, the last reaction is the most serious and occurs in a fraction of 1% of the patients. Agranulocytosis, like the other adverse reactions, generally occurs within the first few weeks or months of treatment. It is accompanied by fever and sore throat, and hence, when therapy is begun, the patient should be instructed to discontinue the drug and notify the physician immediately should these symptoms develop. This precaution is more important than the frequent measurement ofleucocytes counts, since agranulocytosis may develop within a day or two. 2 A patient with paranoid schizophrenia and methimazole-controlled Graves' disease, with hallucinatory symptomatology unrestrained by typical neuroleptics was switched to clozapine, a neuroleptic that needs weekly blood cell count for its potential to induce agranulocytosis, and suddently developed granulocytopenia.
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